During the exhibition Grindeks will offer cooperation to other pharmaceutical industry’s representatives, introducing them to its active pharmaceutical ingredients and final dosage forms. One of the areas to be specifically offered for partnering includes promotion of Grindeks’ range of vertically integrated products to cooperation partners from various world regions, especially to those from Grindeks strategic business development markets in the European Union and Southern Asia countries. Such products as oxytocin, zopiclone, imatinib and ursodesoxycholic acid are produced by Grindeks within a vertically integrated cycle from their active ingredient to final dosage form, thus both product forms are offered to clients, while lenalidomide, an anticancer drug currently under development, will be offered in a future perspective.

The Chairman of the Board of JSC Grindeks Juris Bundulis: “For us, participation in the world’s largest pharma trade show annually is among the top events to explore new partnering opportunities, as well as to strengthen existing partnerships. We look forward to meeting more than two and a half thousands of pharmaceutical industry representatives and introduce them to benefits of Grindeks’ products and their excellent quality that has allowed them to reach patients in more than 70 countries worldwide.”

During the exhibition Kalceks, a subsidiary of Grindeks specialising in manufacturing of CNS and cardiovascular injectables, intends to expand its opportunities of business activity in new markets. The best known Kalceks products are solution for injections of fentanyl, morphine sulfate and magnesium sulfate. This year magnesium sulfate solution for injection produced by Kalceks was prequalified by the World Health Organisation. Also, a number of new injectable preparations will be presented at the exhibition that have been added to the Kalceks product portfolio this year, e.g., a vitamin B complex usable in treatment of neuralgic diseases. Meanwhile, registration process for such products as an anti-inflammatory dexketoprofen solution for injections and atracurium besilate used as a muscle relaxant during surgical treatment is expected to be complete soon, as well as for other medicines that currently are in the process of international registration.